The Role of Immunotherapy in Early-Stage NSCLC

Opinion
Video

The Oncology Brothers and Patrick Forde, MBBCh, outline immunotherapy options for patients with non–small cell lung cancer and the role of PD-L1 in informing treatment decisions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
4 experts in this video
Related Content
A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
September 12th 2025
Podcast
Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Jax DiEugenio
September 12th 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
September 12th 2025
Podcast
Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 12th 2025
Article
Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

Ariana Pelosci
September 12th 2025
Article